High-density lipoprotein mimetics: Promises and challenges

Biochemical Journal

Volumn 472, Issue 3, 2015, Pages 249-259

  Sviridov, Dmitri ^a   Remaley, Alan T ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Apolipoproteins; Atherosclerosis; Cholesterolmetabolism; Lipoprotein metabolism; Peptides.

Indexed keywords

HIGH DENSITY LIPOPROTEIN; PEPTIDOMIMETIC AGENT;

ANIMAL; DRUG DESIGN; HUMAN;

ANIMALS; DRUG DESIGN; HUMANS; LIPOPROTEINS, HDL; PEPTIDOMIMETICS;

EID: 84955454326     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20150832     Document Type: Review

References (106)

1. Rye, K.-A. And Barter, P.J. (2014) Cardioprotective functions of HDLs. J. Lipid Res. 55, 168-179
2. Sviridov, D., Mukhamedova, N., Remaley, A.T., Chin-Dusting, J. And Nestel, P. (2008) Antiatherogenic functionality of high density lipoprotein: how much versus how good. J. Atheroscler. Thromb. 15, 52-62
3. Vaisar, T., Pennathur, S., Green, P.S., Gharib, S.A., Hoofnagle, A.N., Cheung, M.C., Byun, J., Vuletic, S., Kassim, S., Singh, P. et al. (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117, 746-756
4. Vickers, K.C., Palmisano, B.T., Shoucri, B.M., Shamburek, R.D. And Remaley, A.T. (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423-433
5. McMahon, K.M., Foit, L., Angeloni, N.L., Giles, F.J., Gordon, L.I. And Thaxton, C.S. (2015) Synthetic high-density lipoprotein-like nanoparticles as cancer therapy. Cancer Treat. Res. 166, 129-150
6. Yang, S., Damiano, M.G., Zhang, H., Tripathy, S., Luthi, A.J., Rink, J.S., Ugolkov, A.V., Singh, A.T.K., Dave, S.S., Gordon, L.I. And Thaxton, C.S. (2013) Biomimetic, synthetic HDL nanostructures for lymphoma. Proc. Nat. Acad. Sci. U.S.A. 110, 2511-2516
7. Su, F., Grijalva, V., Navab, K., Ganapathy, E., Meriwether, D., Imaizumi, S., Navab, M., Fogelman, A.M., Reddy, S.T. And Farias-Eisner, R. (2012) HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol. Cancer Therap. 11, 1311-1319
8. Peterson, S.J., Kim, D.H., Li, M., Positano, V., Vanella, L., Rodella, L.F., Piccolomini, F., Puri, N., Gastaldelli, A., Kusmic, C. et al. (2009) The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J. Lipid Res. 50, 1293-1304
9. Handattu, S.P., Garber, D.W., Monroe, C.E., van Groen, T., Kadish, I., Nayyar, G., Cao, D., Palgunachari, M.N., Li, L. And Anantharamaiah, G.M. (2009) Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol. Dis. 34, 525-534
10. Handattu, S.P., Monroe, C.E., Nayyar, G., Palgunachari, M.N., Kadish, I., van Groen, T., Anantharamaiah, G.M. And Garber, D.W. (2013) In vivo and in vitro effects of an apolipoprotein e mimetic peptide on amyloid-beta pathology. J. Alzheimers Dis. 36, 335-347
11. Van Lenten, B.J., Wagner, A.C., Navab, M., Anantharamaiah, G.M., Hui, E.K.-W., Nayak, D.P. And Fogelman, A.M. (2004) D-4F, an Apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza a infection of human type II pneumocytes. Circulation 110, 3252-3258
12. Moreira, R.S., Irigoyen, M., Sanches, T.R., Volpini, R.A., Camara, N.O., Malheiros, D.M., Shimizu, M.H., Seguro, A.C. And Andrade, L. (2014) Apolipoprotein A-I mimetic peptide 4F attenuates kidney injury, heart injury, and endothelial dysfunction in sepsis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 307, R514-R524
13. Hsieh, G.R., Schnickel, G.T., Garcia, C., Shefizadeh, A., Fishbein, M.C. And Ardehali, A. (2007) Inflammation/oxidation in chronic rejection: Apolipoprotein a-i mimetic peptide reduces chronic rejection of transplanted hearts. Transplantation 84, 238-243
14. Nandedkar, S.D., Weihrauch, D., Xu, H., Shi, Y., Feroah, T., Hutchins, W., Rickaby, D.A., Duzgunes, N., Hillery, C.A., Konduri, K.S. And Pritchard, K.A. (2011) D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. J. Lipid Res. 52, 499-508
15. Charles-Schoeman, C., Banquerigo, M.L., Hama, S., Navab, M., Park, G.S., Van Lenten, B.J., Wagner, A.C., Fogelman, A.M. And Brahn, E. (2008) Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin. Immunol. 127, 234-244
16. Gomaraschi, M., Calabresi, L., Rossoni, G., Iametti, S., Franceschini, G., Stonik, J.A. And Remaley, A.T. (2008) Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J. Pharmacol. Exp. Ther. 324, 776-783
17. Sharma, S., Umar, S., Potus, F., Iorga, A., Wong, G., Meriwether, D., Breuils-Bonnet, S., Mai, D., Navab, K., Ross, D. et al. (2014) Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation 130, 776-785
18. Sanchez-Gaytan, B.L., Fay, F., Lobatto, M.E., Tang, J., Ouimet, M., Kim, Y., van der Staay, S.E., van Rijs, S.M., Priem, B., Zhang, L. et al. (2015) HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages. Bioconjug. Chem. 26, 443-451
19. Marrache, S. And Dhar, S. (2013) Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis. Proc. Nat. Acad. Sci. U.S.A. 110, 9445-9450
20. Zhang, Z., Chen, J., Ding, L., Jin, H., Lovell, J.F., Corbin, I.R., Cao, W., Lo, P.C., Yang, M., Tsao, M.S., Luo, Q. And Zheng, G. (2010) HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6, 430-437
21. Diditchenko, S., Gille, A., Pragst, I., Stadler, D., Waelchli, M., Hamilton, R., Leis, A. And Wright, S.D. (2013) Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-Dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 33, 2202-2211
22. Tardif, J.C., Gregoire, J., L'Allier, P, L., Ibrahim, R., Lesperance, J., Heinonen, T.M., Kouz, S., Berry, C., Basser, R., Lavoie, M.A. et al. (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 297, 1675-1682
23. Tardif, J.C., Ballantyne, C.M., Barter, P., Dasseux, J.L., Fayad, Z.A., Guertin, M.C., Kastelein, J.J., Keyserling, C., Klepp, H., Koenig, W. et al. (2014) Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: A randomized trial. Eur. Heart J. 35, 3277-3286
24. Roma, P., Gregg, R.E., Meng, M.S., Ronan, R., Zech, L.A., Franceschini, G., Sirtori, C.R. And Brewer, H.J. (1993) In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia. J. Clin. Invest. 91, 1445-1452
25. Jia, Z., Natarajan, P., Forte, T.M. And Bielicki, J.K. (2002) Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoproteinA-I(Milano). Biochem. Biophys. Res. Commun. 297, 206-213
26. Ohnsorg, P.M., Mary, J.-L., Rohrer, L., Pech, M., Fingerle, J. And von Eckardstein, A. (2011) Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin:cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells. Biochim. Biophys. Acta 1811, 1115-1123
27. Murphy, A.J., Hoang, A., Aprico, A., Sviridov, D. And Chin-Dusting, J. (2013) Anti-inflammatory functions of apolipoprotein A-I and high-density lipoprotein are preserved in trimeric apolipoprotein A-I. J. Pharmacol. Exp. Ther. 344, 41-49
28. Graversen, J.H., Laurberg, J.M., Andersen, M.H., Falk, E., Nieland, J., Christensen, J., Etzerodt, M., Thogersen, H.C. And Moestrup, S.K. (2008) Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties. J. Cardiovasc. Pharmacol. 51, 170-177
29. Murphy, A.J., Funt, S., Gorman, D., Tall, A.R. And Wang, N. (2013) Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity. Circ. Res. 113, e1-e9
30. Uehara, Y., Ando, S., Yahiro, E., Oniki, K., Ayaori, M., Abe, S., Kawachi, E., Zhang, B., Shioi, S., Tanigawa, H. et al. (2013) FAMP, a Novel ApoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in ApoE-deficient mice. J. Am. Heart Assoc. 2, e000048
31. Bielicki, J.K., Zhang, H., Cortez, Y., Zheng, Y., Narayanaswami, V., Patel, A., Johansson, J. And Azhar, S. (2010) A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J. Lipid Res. 51, 1496-1503
32. Sviridov, D.O., Ikpot, I.Z., Stonik, J., Drake, S.K., Amar, M., Osei-Hwedieh, D.O., Piszczek, G., Turner, S. And Remaley, A.T. (2011) Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter. Biochem. Biophys. Res. Commun. 410, 446-451
33. Zhao, Y., Black, A.S., Bonnet, D.J., Maryanoff, B.E., Curtiss, L.K., Leman, L.J. And Ghadiri, M.R. (2014) In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. J. Lipid Res. 55, 2053-2063
34. Gupta, H., White, C.R., Handattu, S., Garber, D.W., Datta, G., Chaddha, M., Dai, L., Gianturco, S.H., Bradley, W.A. And Anantharamaiah, G.M. (2005) Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation 111, 3112-3118
35. Handattu, S.P., Datta, G., Epand, R.M., Epand, R.F., Palgunachari, M.N., Mishra, V.K., Monroe, C.E., Keenum, T.D., Chaddha, M., Anantharamaiah, G.M. And Garber, D.W. (2010) Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice. J. Lipid. Res. 51, 3491-3499
36. Zhao, W., Du, F., Zhang, M., Sun, S., Yu, H. And Fan, D. (2011) A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing activity. Exp. Biol. Med. 236, 1468-1476
37. Amar, M.J., Sakurai, T., Sakurai-Ikuta, A., Sviridov, D., Freeman, L., Ahsan, L. And Remaley, A.T. (2015) A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice. J. Pharmacol. Exp. Ther. 352, 227-235
38. Chung, B.H., Anatharamaiah, G.M., Brouillette, C.G., Nishida, T. And Segrest, J.P. (1985) Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with function. J. Biol. Chem. 260, 10256-10262
39. Mendez, A.J., Anantharamaiah, G.M., Segrest, J.P. And Oram, J.F. (1994) Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J. Clin. Invest. 94, 1698-1705
40. Datta, G., Chaddha, M., Hama, S., Navab, M., Fogelman, A.M., Garber, D.W., Mishra, V.K., Epand, R.M., Epand, R.F., Lund-Katz, S. et al. (2001) Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 42, 1096-1104
41. Di Bartolo, B.A., Nicholls, S.J., Bao, S., Rye, K.-A., Heather, A.K., Barter, P.J. And Bursill, C. (2011) The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis 217, 395-400
42. Mishra, V.K., Palgunachari, M.N., Lund-Katz, S., Phillips, M.C., Segrest, J.P. And Anantharamaiah, G.M. (1995) Effect of the arrangement of tandem repeating units of class A amphipathic alpha-helixes on lipid interaction. J. Biol. Chem. 270, 1602-1611
43. Wool, G.D., Vaisar, T., Reardon, C.A. And Getz, G.S. (2009) An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J. Lipid Res. 50, 1889-1900
44. Sethi, A.A., Stonik, J.A., Thomas, F., Demosky, S.J., Amar, M., Neufeld, E., Brewer, H.B., Davidson, W.S., D'Souza, W., Sviridov, D. And Remaley, A.T. (2008) Asymmetry in the lipid affinity of bihelical amphipathic peptides: A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J. Biol. Chem. 283, 32273-32282
45. Navab, M., Anantharamaiah, G.M., Hama, S., Garber, D.W., Chaddha, M., Hough, G., Lallone, R. And Fogelman, A.M. (2002) Oral administration of an apo A-I Mimetic peptide synthesized from D-Amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105, 290-292
46. Navab, M., Ruchala, P., Waring, A.J., Lehrer, R.I., Hama, S., Hough, G., Palgunachari, M.N., Anantharamaiah, G.M. And Fogelman, A.M. (2009) A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-Amino acids. J. Lipid Res. 50, 1538-1547
47. D'Souza, W., Stonik, J.A., Murphy, A., Demosky, S.J., Sethi, A.A., Moore, X.L., Chin-Dusting, J., Remaley, A.T. And Sviridov, D. (2010) Structure/function relationships of apolipoprotein A-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. Circ. Res. 107, 217-227
48. Atger, V.M., de la Llera Moya, M., Stoudt, G.W., Rodrigueza, W.V., Phillips, M.C. And Rothblat, G.H. (1997) Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells. J. Clin. Invest. 99, 773-780
49. Rodrigueza, W.V., Mazany, K.D., Essenburg, A.D., Pape, M.E., Rea, T.J., Bisgaier, C.L. And Williams, K.J. (1997) Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17, 2132-2139
50. Thaxton, C.S., Daniel, W.L., Giljohann, D.A., Thomas, A.D. And Mirkin, C.A. (2009) Templated spherical high density lipoprotein nanoparticles. J. Am. Chem. Soc. 131, 1384-1385
51. Luthi, A.J., Zhang, H., Kim, D., Giljohann, D.A., Mirkin, C.A. And Thaxton, C.S. (2012) Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS Nano. 6, 276-285
52. Hoang, A., Drew, B.G., Low, H., Remaley, A.T., Nestel, P., Kingwell, B.A. And Sviridov, D. (2012) Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur. Heart J. 33, 657-665
53. Gille, A., Easton, R., D'Andrea, D., Wright, S.D. And Shear, C.L. (2014) CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler. Thromb. Vasc. Biol. 34, 2106-2114
54. Iwata, A., Miura, S.-i., Zhang, B., Imaizumi, S., Uehara, Y., Shiomi, M. And Saku, K. (2011) Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. Atherosclerosis 218, 300-307
55. Amar, M.J. A., D'Souza, W., Turner, S., Demosky, S., Sviridov, D., Stonik, J., Luchoomun, J., Voogt, J., Hellerstein, M., Sviridov, D. And Remaley, A.T. (2010) 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J. Pharmacol. Exp. Ther. 334, 634-641
56. Luthi, A.J., Lyssenko, N.N., Quach, D., McMahon, K.M., Millar, J.S., Vickers, K.C., Rader, D.J., Phillips, M.C., Mirkin, C.A. And Thaxton, C.S. (2015) Robust passive and active efflux of cellular cholesterol to a designer functional mimic of high density lipoprotein. J. Lipid Res. 56, 972-985
57. Hafiane, A., Bielicki, J.K., Johansson, J.O. And Genest, J. (2014) Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro. Biochim. Biophys. Acta 1841, 1498-1512
58. Tang, C., Vaughan, A.M., Anantharamaiah, G.M. And Oram, J.F. (2006) Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J. Lipid Res. 47, 107-114
59. Navab, M., Anantharamaiah, G.M., Reddy, S.T., Hama, S., Hough, G., Grijalva, V.R., Wagner, A.C., Frank, J.S., Datta, G., Garber, D. And Fogelman, A.M. (2004) Oral D-4F causes formation of pre-{beta} high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109, 3215-3220
60. Sharifov, O.F., Nayyar, G., Garber, D.W., Handattu, S.P., Mishra, V.K., Goldberg, D., Anantharamaiah, G.M. And Gupta, H. (2011) Apolipoprotein E mimetics and cholesterol-lowering properties. Am. J. Cardiovasc. Drugs 11, 371-381
61. Tabet, F., Remaley, A.T., Segaliny, A.I., Millet, J., Yan, L., Nakhla, S., Barter, P.J., Rye, K.-A. And Lambert, G. (2010) The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler. Thromb. Vasc. Biol. 30, 246-252
62. Datta, G., White, C.R., Dashti, N., Chaddha, M., Palgunachari, M.N., Gupta, H., Handattu, S.P., Garber, D.W. And Anantharamaiah, G.M. (2010) Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH2. Atherosclerosis 208, 134-141
63. Smythies, L.E., White, C.R., Maheshwari, A., Palgunachari, M.N., Anantharamaiah, G.M., Chaddha, M., Kurundkar, A.R. And Datta, G. (2010) The apolipoprotein A-I mimetic, 4F, alters the function of human monocyte-derived macrophages. Am. J. Physiol. Cell Physiol. 298, 1538-1548
64. Madenspacher, J.H., Azzam, K.M., Gong, W., Gowdy, K.M., Vitek, M.P., Laskowitz, D.T., Remaley, A.T., Wang, J.M. And Fessler, M.B. (2012) Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity. J. Biol. Chem. 287, 43730-43740
65. Vaziri, N.D., Moradi, H., Pahl, M.V., Fogelman, A.M. And Navab, M. (2009) In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int. 76, 437-444
66. White, C.R., Smythies, L.E., Crossman, D.K., Palgunachari, M.N., Anantharamaiah, G.M. And Datta, G. (2012) Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F. Arterioscler. Thromb. Vasc. Biol. 32, 2631-2639
67. Kruger, A.L., Peterson, S., Turkseven, S., Kaminski, P.M., Zhang, F.F., Quan, S., Wolin, M.S. And Abraham, N.G. (2005) D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 111, 3126-3134
68. Zhang, Z., Datta, G., Zhang, Y., Miller, A.P., Mochon, P., Chen, Y.-F., Chatham, J., Anantharamaiah, G.M. And White, C.R. (2009) Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am. J. Physiol. Heart Circ. Physiol. 297, H866-H873
69. Nguyen, S.D., Jeong, T.S. And Sok, D.E. (2006) Apolipoprotein A-I-mimetic peptides with antioxidant actions. Arch. Biochem. Biophys. 451, 34-42
70. Mishra, V.K., Palgunachari, M.N., McPherson, D.T. And Anantharamaiah, G.M. (2013) Lipid complex of apolipoprotein A-I mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity and stability. Biochem. Biophys. Res. Comm. 430, 975-980
71. Van Lenten, B.J., Wagner, A.C., Jung, C.-L., Ruchala, P., Waring, A.J., Lehrer, R.I., Watson, A.D., Hama, S., Navab, M., Anantharamaiah, G.M. And Fogelman, A.M. (2008) Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J. Lipid Res. 49, 2302-2311
72. Meriwether, D., Imaizumi, S., Grijalva, V., Hough, G., Vakili, L., Anantharamaiah, G.M., Farias-Eisner, R., Navab, M., Fogelman, A.M., Reddy, S.T. And Shechter, I. (2011) Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma. J. Lipid Res. 52, 1795-1809
73. Yao, S., Tian, H., Miao, C., Zhang, D.-W., Zhao, L., Li, Y., Yang, N., Jiao, P., Sang, H., Guo, S., Wang, Y. And Qin, S. (2015) D4F alleviates macrophage-derived foam cell apoptosis by inhibiting CD36 expression and ER stress-CHOP pathway. J. Lipid Res. 56, 836-847
74. Zhang, Z., Qun, J., Cao, C., Wang, J., Li, W., Wu, Y., Du, L., Zhao, P. And Gong, K. (2012) Apolipoprotein A-I mimetic peptide D-4F promotes human endothelial progenitor cell proliferation, migration, adhesion though eNOS/NO pathway. Mol. Biol. Rep. 39, 4445-4454
75. Dai, L., Datta, G., Zhang, Z., Gupta, H., Patel, R., Honavar, J., Modi, S., Wyss, J.M., Palgunachari, M., Anantharamaiah, G.M. And White, C.R. (2010) The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J. Lipid Res. 51, 2695-2705
76. Ou, Z., Ou, J., Ackerman, A.W., Oldham, K.T. And Pritchard, Jr, K.A. (2003) L-4F, an Apolipoprotein A-1 Mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-Treated endothelial cells. Circulation 107, 1520-1524
77. Ou, J., Wang, J., Xu, H., Ou, Z., Sorci-Thomas, M.G., Jones, D.W., Signorino, P., Densmore, J.C., Kaul, S., Oldham, K.T. And Pritchard, Jr, K.A. (2005) Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on western diet. Circ. Res. 97, 1190-1197
78. Buga, G.M., Navab, M., Imaizumi, S., Reddy, S.T., Yekta, B., Hough, G., Chanslor, S., Anantharamaiah, G.M. And Fogelman, A.M. (2010) L-4F Alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation. Arterioscler. Thromb. Vasc. Biol. 30, 283-289
79. Nguyen, S.D., Javanainen, M., Rissanen, S., Zhao, H., Huusko, J., Kivelä, A.M., Ylä-Herttuala, S., Navab, M., Fogelman, A.M., Vattulainen, I. et al. (2015) Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation. J. Lipid Res. 56, 1206-1221
80. Navab, M., Reddy, S.T., Anantharamaiah, G.M., Imaizumi, S., Hough, G., Hama, S. And Fogelman, A.M. (2011) Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J. Lipid Res. 52, 1200-1210
81. Navab, M., Reddy, S.T., Van Lenten, B.J., Buga, G.M., Hough, G., Wagner, A.C. And Fogelman, A.M. (2012) High-Density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism. Arterioscler. Thromb. Vasc. Biol. 32, 2553-2560
82. Duivenvoorden, R., Tang, J., Cormode, D.P., Mieszawska, A.J., Izquierdo-Garcia, D., Ozcan, C., Otten, M.J., Zaidi, N., Lobatto, M.E., van Rijs, S.M. et al. (2014) A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun. 5, 3065
83. Shah, P.K., Nilsson, J., Kaul, S., Fishbein, M.C., Ageland, H., Hamsten, A., Johansson, J., Karpe, F. And Cercek, B. (1998) Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97, 780-785
84. Shah, P.K., Yano, J., Reyes, O., Chyu, K.-Y., Kaul, S., Bisgaier, C.L., Drake, S. And Cercek, B. (2001) High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice : potential implications for acute plaque stabilization. Circulation 103, 3047-3050
85. Chiesa, G., Monteggia, E., Marchesi, M., Lorenzon, P., Laucello, M., Lorusso, V., Di Mario, C., Karvouni, E., Newton, R.S., Bisgaier, C.L. et al. (2002) Recombinant apolipoprotein A-IMilano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ. Res. 90, 974-980
86. Ibanez, B., Giannarelli, C., Cimmino, G., Santos-Gallego, C.G., Alique, M., Pinero, A., Vilahur, G., Fuster, V., Badimon, L. And Badimon, J.J. (2012) Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-Type. Atherosclerosis 220, 72-77
87. Tardy, C., Goffinet, M., Boubekeur, N., Ackermann, R., Sy, G., Bluteau, A., Cholez, G., Keyserling, C., Lalwani, N., Paolini, J.F. et al. (2014) CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis 232, 110-118
88. Morgantini, C., Imaizumi, S., Grijalva, V., Navab, M., Fogelman, A.M. And Reddy, S.T. (2010) Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes. Diabetes 59, 3223-3228
89. Chattopadhyay, A., Navab, M., Hough, G., Gao, F., Meriwether, D., Grijalva, V., Springstead, J.R., Palgnachari, M.N., Namiri-Kalantari, R., Su, F. et al. (2013) A novel approach to oral apoA-I mimetic therapy. J. Lipid Res. 54, 995-1010
90. Ditiatkovski, M., D'Souza, W., Kesani, R., Chin-Dusting, J., de Haan, J.B., Remaley, A. And Sviridov, D. (2013) An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. PLoS ONE 8, e68802
91. Handattu, S.P., Nayyar, G., Garber, D.W., Palgunachari, M.N., Monroe, C.E., Keenum, T.D., Mishra, V.K., Datta, G. And Anantharamaiah, G.M. (2013) Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis 227, 58-64
92. Gupta, H., White, C.R., Handattu, S., Garber, D.W., Datta, G., Chaddha, M., Dai, L., Gianturco, S.H., Bradley, W.A. And Anantharamaiah, G.M. (2005) Apolipoprotein E mimetic Peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation 111, 3112-3118
93. Nayyar, G., Garber, D.W., Palgunachari, M.N., Monroe, C.E., Keenum, T.D., Handattu, S.P., Mishra, V.K. And Anantharamaiah, G.M. (2012) Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice. Atherosclerosis 224, 326-331
94. Nissen, S.E., Tsunoda, T., Tuzcu, E.M., Schoenhagen, P., Cooper, C.J., Yasin, M., Eaton, G.M., Lauer, M.A., Sheldon, W.S., Grines, C.L. et al. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 290, 2292-2300
95. Easton, R., Gille, A., D'Andrea, D., Davis, R., Wright, S.D. And Shear, C. (2014) A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J. Clin. Pharmacol. 54, 301-310
96. Shaw, J.A., Bobik, A., Murphy, A., Kanellakis, P., Blombery, P., Mukhamedova, N., Woollard, K., Lyon, S., Sviridov, D. And Dart, A.M. (2008) Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 103, 1084-1091
97. Kootte, R.S., Smits, L.P., van der Valk, F.M., Dasseux, J.-L., Keyserling, C.H., Barbaras, R., Paolini, J.F., Santos, R.D., van Dijk, T.H., Dallinga-van Thie, G.M. et al. (2015) Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J. Lipid Res. 56, 703-712
98. Bloedon, L.T., Dunbar, R., Duffy, D., Pinell-Salles, P., Norris, R., DeGroot, B.J., Movva, R., Navab, M., Fogelman, A.M. And Rader, D.J. (2008) Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49, 1344-1352
99. Watson, C.E., Weissbach, N., Kjems, L., Ayalasomayajula, S., Zhang, Y., Chang, I., Navab, M., Hama, S., Hough, G., Reddy, S.T. et al. (2011) Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res. 52, 361-373
100. Ou, J., Ou, Z., Jones, D.W., Holzhauer, S., Hatoum, O.A., Ackerman, A.W., Weihrauch, D.W., Gutterman, D.D., Guice, K., Oldham, K.T. et al. (2003) L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 107, 2337-2341
101. Weihrauch, D., Xu, H., Shi, Y., Wang, J., Brien, J., Jones, D.W., Kaul, S., Komorowski, R.A., Csuka, M.E., Oldham, K.T. And Pritchard, K.A. (2007) Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am. J. Physiol. Heart Circ. Physiol. 293, H1432-H1441
102. Drew, B.G., Duffy, S.J., Formosa, M.F., Natoli, A.K., Henstridge, D.C., Penfold, S.A., Thomas, W.G., Mukhamedova, N., de Courten, B., Forbes, J.M. et al. (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119, 2103-2111
103. Calkin, A.C., Drew, B.G., Ono, A., Duffy, S.J., Gordon, M.V., Schoenwaelder, S.M., Sviridov, D., Cooper, M.E., Kingwell, B.A. And Jackson, S.P. (2009) Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 120, 2095-2104
104. Sviridov, D., Hoang, A., Sawyer, W. And Fidge, N. (2000) Identification of a sequence of apolipoprotein A-I associated with activation of lecithin:cholesterol acyltransferase. J. Biol. Chem. 275, 19707-19712
105. Silva, R.A. G.D., Huang, R., Morris, J., Fang, J., Gracheva, E.O., Ren, G., Kontush, A., Jerome, W.G., Rye, K.-A. And Davidson, W.S. (2008) Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc. Nat. Acad. Sci. U.S.A. 105, 12176-12181
106. Sviridov, D. (2014) High density lipoprotein-A hero, a mirage or a witness? Front. Cardiovasc. Med. 1, 1-4